Parthenon Therapeutics Showcases New Precision Oncology Technology Designed to Breakdown Barriers in Immune-excluded Tumors

– Patient-derived biomarker and preclinical data demonstrate significant opportunity to address immune-excluded tumors, such as colorectal, NSCLC, ovarian, pancreas, and TNBC

– First in human clinical trial of lead asset, PRTH-101, expected to initiate 3Q23

BOSTON–(BUSINESS WIRE)–Parthenon Therapeutics, a precision oncology company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today unveiled its precision medicine approach to address cancers with hight unmet need, at the Stifel Healthcare Conference.

“We are delighted to showcase our pipeline and technology to the scientific community and anticipate that we will pioneer a new approach to treating patients with immune-excluded tumors. Specifically, immune exclusivity describes a distinct category of TME where a patient’s T-cells are unable to attack a tumor due to the formation of a barrier around the tumor cells. Our data have shown over 50% of solid tumors are immune-excluded, indicating a significant unmet need for these patients,” said Laurent Audoly, co-founder and Chief Executive Officer of Parthenon Therapeutics. “We also presented our lead asset, PRTH-101, which targets DDR1 (Discoidin Domain Receptor 1) to open up the mechanical barrier that characterizes immune-excluded tumors, and thus make the tumors vulnerable to treatment. We are excited to be developing one of the first therapeutics and patient selection strategy to address this class of tumors, and we anticipate providing more details in the upcoming months. Notably, the second half of 2023 will be a catalyst as we will initiate our first-in-human clinical study in a well-defined patient population.”

About Parthenon Therapeutics

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, ground breaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information visit parthenontx.com and LinkedIn.

Contacts

Investors

Gilmartin Group
Jessica Vo

Email: [email protected]

Media Enquiries

Parthenon
[email protected]

Optimum Strategic Communications
Mary Clark, Charlotte Hepburne-Scott, Zoe Bolt

Email: [email protected]
Phone: +44 203 882 9621